ICB combined with chemotherapy
toxicity
CPS, CERVICAL CANCER, METASTATIC CERVICAL CANCER
Chemotherapy is the fundamental therapy for recurrent or primary metastatic cervical cancer. In the history of chemotherapy for cervical cancer, cisplatin monotherapy and then a combination of cisplatin and paclitaxel were considered the standard therapies in sequence (Pembrolizumab plus platinum-based chemotherapy. The phase III clinical trial KEYNOTE-826 (NCT03635567) is the leading one in this treatment pattern. Compared with platinum-based chemotherapy plus placebo with or without Bevacizumab, patients treated by platinum-based chemotherapy plus Pembrolizumab with or without Bevacizumab showed better mPFSs (10.4 months versus 8.2 months; HR=0.65, 95% CI: 0.53-0.79, P<0.001) and mOSs (24.4 months versus 16.5 months; HR=0.67, 95% CI: 0.54-0.84, P<0.001). Through further analysis of subgroups, considerable benefits were gained in the subgroup PD-L1 combined positive score (CPS) of 1 or more, the subgroup PD-L1 CPS of 10 or more, and all the incorporated populations (HLX10 plus albumin-bound paclitaxel. A phase II clinical study (NCT04150575) investigated HLX10 (a new anti-PD-1 antibody) combined with albumin and paclitaxel as second-line therapy for advanced cervical cancer or patients with advanced cervical cancer who could not tolerate toxicity (Other ongoing phase III clinical trials using this pattern of treatment include NCT03556839 (